<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071837</url>
  </required_header>
  <id_info>
    <org_study_id>APG101_CD_002</org_study_id>
    <nct_id>NCT01071837</nct_id>
  </id_info>
  <brief_title>APG101 in Glioblastoma</brief_title>
  <official_title>A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apogenix GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apogenix GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of APG101 + reirradiation (RT) versus reirradiation. Patients
      suffering from a malignant brain tumor called glioblastoma having a first or second
      progression can be included. They will be randomized to RT or RT + APG101.

      APG101 is a fusion protein (similar to an antibody) and will be administered as a weekly
      infusion. Patients can stay in this study as long as they benefit from the participation (no
      fixed end).

      In this trial, 30-35 sites in Germany, Austria and Russia take part.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II trial, patients with a recurrence / progression of glioblastoma (first or
      second progression) either not being eligible for tumour resection or having macroscopic
      residual tumour after resection of the recurrence can be included (tumor size must 1-4 cm in
      T1-weighted MRI). They must be candidates for a re-irradiation and will then be randomized in
      a 1:2 ratio to re-irradiation alone or re-irradiation + 400mg APG101 as a weekly intravenous
      infusion.

      Radiotherapy (RT) is considered standard of care and not a study procedure. As prior
      therapies, a first radiotherapy (maximal dose of 60 Gy; at least 8 months since the end of
      preirradiation), a prior surgery (at least for histology) and at least one
      Temozolomide-containing chemotherapy are mandatory; patients with prior treatment with
      bevacizumab, iodine seeds and/or brachytherapy are not eligible. The patients' steroid dose
      must be stable or decreasing upon inclusion.

      The number of patients to be included in this study is up to 83 (depending on the statistical
      2-step SIMON design).

      Primary objective: 6 months rate of progression free survival (PFS6). Subjects can
      participate in this study as long as a clinical benefit is considered by the treating
      physician.

      MRI tumour imaging will be carried out every 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months rate of progression free survival (PFS6)</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of APG101</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>until progression of underlying disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rates (OR)</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR) in responders</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>until study and after end of study (by 8-weekly phone calls)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Re-Irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Re-Irradiation + APG101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG101</intervention_name>
    <description>400mg weekly as intravenous infusion</description>
    <arm_group_label>Re-Irradiation + APG101</arm_group_label>
    <other_name>Recombinant fusion protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood drawing</intervention_name>
    <description>Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)</description>
    <arm_group_label>Re-Irradiation</arm_group_label>
    <other_name>n.a.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with a recurrence / progression of glioblastoma either not
             being eligible for tumour resection or having macroscopic residual tumour after
             resection of the recurrence

          -  Diagnosis of glioblastoma must be proven histologically and progress must be
             documented by MRI. MRI images must not be older than 2 weeks before first dosing/start
             of RT

          -  Not more than two prior therapy regimens including one or two resections, one or two
             chemotherapies of which one must have been TMZ-containing and one radiotherapy (RT)
             for the brain tumour

          -  Previous irradiation therapy of the primary tumour with a maximal dose of 60 Gy; at
             least 8 months since the end of preirradiation

          -  Candidate for reirradiation with recurrent tumour visible on MRI-T1 (Gd) and with the
             largest diameter measuring 1 cm to 4 cm

          -  Informed consent

          -  Age at least 18 years, smoking or non-smoking, of any ethnic origin

          -  Karnofsky performance index (KPI) ≥ 60%

          -  Neutrophile counts &gt; 1500/μl / Platelet counts &gt; 80.000/μl / Haemoglobin &gt; 10 g/dl /
             Serum creatinine &lt; 1.5-fold upper normal range / Bilirubin, AST or ALT &lt; 2,5-fold
             upper normal range unless attributed to anticonvulsants / Alkaline phosphatase &lt;
             2,5-fold upper normal range

          -  Adequate contraception

          -  Stable or decreasing treatment with steroids within 5 days before treatment start

        Exclusion Criteria:

          -  More than one RT of brain, prior first radiotherapy with more than 60 Gy

          -  Cumulative total dose on the optical chiasm &gt;54 Gy for 2 Gy/fraction, α/β=2

          -  Prior treatment with bevacizumab, iodine seeds and/or brachytherapy

          -  Unable to undergo MRI

          -  Past medical history of diseases with poor prognosis according to the judgement of the
             Investigator, e.g. severe coronary heart disease, severe diabetes, immune deficiency,
             residual deficits after stroke, severe mental retardation

          -  HIV or hepatitis infection

          -  Pregnancy or breast feeding

          -  Treatment within any other clinical trial parallel to the treatment phase of the
             current study or within 30 days before inclusion

          -  Known active coronary artery disease, significant cardiac arrhythmias or severe
             congestive heart failure (NYHA class III - IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Wick, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Heidelberg, Dept. of Neurooncology, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Graz, Universitätsklinik für Neurologie Landeskrankenhaus Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Neurologie, Landeskrankenhaus Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesnervenklinik Wagner-Jauregg, Innere Medizin mit Neuroonkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien, Klinische Onkologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin, Klinik für Neurochirugie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik am Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bonn, Schwerpunkt klinische Neuroonkologie</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden, Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt/Oder, Klinik für Strahlentherapie/Radioonkologie</name>
      <address>
        <city>Frankfurt/Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Hamburg, Klinik für Neurochirugie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Heidelberg, Abteilung Neuroonkologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig, Klinik für Strahlentherapie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim, Klinik für Neurochirurgie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg, Klinik für Neurologie</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Campus Großhadern &amp; Campus Innenstadt</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Strahlentherapie/Radiologische Onkologie, Klinikum rechts der Isar, TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Kliniken München GmbH, Klinikum Bogenhausen, Abt. Neurochirurgie</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik der Universität Regensburg, Im Bezirksklinikum</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Neurozentrum Neurochirurgie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tuebingen, Strahlenonkologie</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Ulm, Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

